By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

InterMune, Inc. 

3280 Bayshore Boulevard

Brisbane  California  94005  U.S.A.
Phone: 415-466-2200 Fax: 415-466-2329


SEARCH JOBS
InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a product portfolio addressing IPF and HCV infections. The pulmonology portfolio includes Actimmune®, which is being evaluated in the INSPIRE Trial, a Phase III study in patients with IPF, and pirfenidone, which is also being developed for the treatment of IPF. The hepatology portfolio includes the lead HCV protease inhibitor compound (ITMN B), a second-generation HCV protease inhibitor program, and a research program evaluating a new target in hepatology.

For additional information about InterMune and its R&D pipeline, please visit: www.intermune.com


Key Statistics


Email:
Ownership: Public

Web Site: InterMune, Inc.
Employees:
Symbol: ITMN
 




Segment
Drug Discovery





Company News
InterMune, Inc. (ITMN) Announces Anticipated Fundamental Change For 5.00% Convertible Senior Notes Due 2015 9/5/2014 12:52:44 PM
InterMune, Inc. (ITMN) CEO: Bittersweet Ending To A Biotech Comeback Story 8/26/2014 6:33:46 AM
Roche (RHHBY) Pays $8.3 Billion For Bay Area's InterMune, Inc. (ITMN), Pledges To Keep Employees 8/24/2014 7:38:32 PM
InterMune, Inc. (ITMN) Goes Up On The Block; GlaxoSmithKline (GSK), Roche (RHHBY), Sanofi (France) (SAN.PA) Line Up 8/14/2014 6:09:07 AM
InterMune, Inc. (ITMN) Reports Second Quarter 2014 Financial Results And Business Highlights 8/7/2014 8:29:51 AM
InterMune, Inc. (ITMN) To Release Second Quarter Financial Results On August 6 7/28/2014 8:41:32 AM
InterMune, Inc. (ITMN) Grabs FDA Breakthough Therapy Designation For IPF Drug Pirfenidone 7/17/2014 10:50:06 AM
InterMune, Inc. (ITMN) Announces Resubmission Of NDA For Pirfenidone For The Treatment Of Patients With IPF 5/27/2014 9:20:00 AM
InterMune, Inc. (ITMN) Announces Additional Pirfenidone Data In Idiopathic Pulmonary Fibrosis 5/21/2014 9:14:49 AM
InterMune, Inc. (ITMN) Release: Phase 3 ASCEND Study Of Pirfenidone In Idiopathic Pulmonary Fibrosis Presented At American Thoracic Society And Published The New England Journal of Medicine 5/19/2014 1:13:02 PM
12345678910...
//-->